Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Primary Objective - Assess the pathological complete response rate for resectable Merkel cell carcinoma treated with the combination of pembrolizumab and lenvatinib in the neoadjuvant setting. Secondary Objective - Assess the progression free survival of resectable Merkel cell carcinoma treated with neoadjuvant pembrolizumab and lenvatinib
E7080 (Lenvatinib); Lenvatinib (Lenvima); Pembrolizumab (Keytruda)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.